Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ACT-078573

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Drug and Alcohol Dependence 156 (2015) e183–e245 e245 OX1/OX2 receptor antagonist ACT-078573 and the OX2 selective antagonist TCS… Expand
Highly Cited
2014
Highly Cited
2014
To examine the role of orexin-1 and orexin-2 receptor activity on ethanol self-administration, compounds that differentially… Expand
  • figure 1
  • figure 2
  • figure 3
2014
2014
Cannabinoid CB1 and orexin OX1 receptors have been suggested to form heterodimers and oligomers. Aimed at studying these… Expand
2012
2012
In this work the pharmacology and the receptor kinetics of the following orexin receptor antagonists SB-649868, ACT-078573, JNJ… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Review
2010
Review
2010
  • D. Neubauer
  • Current opinion in investigational drugs
  • 2010
  • Corpus ID: 2344908
Almorexant (ACT-078573) is an orally active dual orexin receptor antagonist that is being developed by Actelion Ltd, in… Expand
2007
2007
Brisbare-Roch et al. reply: We agree with Tafti that animal and human orexin deficiency syndromes suggest a theoretical risk of… Expand
  • table 1
2007
2007
  • C. Wiedemann
  • Nature Reviews Neuroscience
  • 2007
  • Corpus ID: 35837576
The sleep–wake cycle in mammals is tightly regulated by the levels of orexins, a family of two hypothalamic peptides. During… Expand
Review
2007
Review
2007
  • C. Wiedemann
  • Nature Reviews Drug Discovery
  • 2007
  • Corpus ID: 24218480
10.1038/nrd2277 The sleep–wake cycle in mammals is tightly regulated by the levels of orexins, a family of two hypothalamic… Expand